Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019163 (hepatitis B)
 38,309 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We administered a combined preparation of hepatitis B virus (HBV) vaccine and Haemophilus influenzae type b (Hib) conjugate vaccine (meningococcal protein conjugate) to 20 healthy adult volunteers. Participants received two doses of vaccine one month apart, and had serum samples drawn each time they received the vaccine and 1 month after the second dose. In 18 of 19 persons who were positive for antibody to hepatitis B surface antigen (anti-HBs), these levels had a median fold increase of 23.4 (range 0.69 to 270) 1 month after the first dose of vaccine. Anti-HBs levels generally fell slightly one month after the second dose was given. All of the study participants initially had detectable levels of antibody to Hib capsular polysaccharide (anti-PRP), and 19 of the 20 exhibited a median fold increase of 11.2 (range 0.81 to 740) in anti-PRP 1 month after vaccination. Over half (65%) continued to demonstrate increased levels of anti-PRP with the second dose of vaccine. Most participants experienced some slight to moderate discomfort at the injection site. The results indicate that the combined Hib/HBV vaccine produces increased antibody levels in healthy adults who have previously been exposed to these two antigens.
 ...
PMID:Safety and immunogenicity of a combined hepatitis B virus-Haemophilus influenzae type B vaccine formulation in healthy adults. 839 80

Universal immunization of infants is essential to the control of hepatitis B in areas of high endemicity where infection commonly occurs in infants and children. It is also an attractive strategy for ultimately reducing hepatitis-B-associated acute and chronic liver disease in areas of lower endemicity where infections occur primarily in adolescents and adults. Integration of hepatitis B vaccine with other routine paediatric immunizations, using flexible scheduling, will enhance compliance while minimizing the need for additional resources. Clinical studies demonstrate that a very high proportion of healthy infants and adults develop a protective level of antibody when given hepatitis B vaccine using a wide range of schedules. Compliance with universal vaccination of infants against hepatitis B may be enhanced by the development of new combination vaccines (e.g. diphtheria-tetanus-pertussis-Haemophilus influenzae b-hepatitis B) that allow complete immunization against several antigens with a minimal number of injections.
 ...
PMID:Control of hepatitis B through routine immunization of infants: the need for flexible schedules and new combination vaccine formulations. 844 68

Active immunization against measles, Haemophilus influenza B, tetanus, diphtheria, hepatitis B, influenza, poliomyelitis, and, when indicated varicella and pneumococcus induces long-lasting immunologic protection in most healthy pediatric vaccine recipients. Among children receiving immunosuppressive therapy for cancer, possible early loss of specific immunity acquired from prior vaccination or disease, and likely diminished responsiveness to initial or booster vaccination must be considered. In addition, the safety of vaccine administration requires separate study in this population. Published evidence demonstrates preservation of vaccine-induced antibody titers against tetanus, diphtheria, poliomyelitis and (in children treated for lymphoma) pneumococcus. In contrast, prior immunity to varicella, influenza, and hepatitis B (when naturally acquired), and measles (acquired by vaccination) is compromised during and/or after antineoplastic therapy. Studies of immunologic protection acquired by prior vaccination against hepatitis B, varicella, and H influenza have not been published. The safety of administering toxoids and inactivated vaccines in this population is well documented. In contrast, morbidity must be expected if live attenuated vaccines (oral polio vaccine, attenuated measles vaccine or attenuated varicella vaccine) are administered to children receiving anti-cancer therapy. The risks of using live vaccines should be measured against demonstrable benefits in any vaccine program. The response to initial or booster immunizations against tetanus and diphtheria are similar to those in healthy children. For all other immunizations reviewed, responsiveness is diminished during periods of chemotherapy, more strikingly in children treated for leukemia than for solid tumors. Antibody responses to these vaccines range from slightly blunted (in the case of H influenza B) to marginal (influenza) or completely useless (pneumococcus and hepatitis B in children treated for leukemia).
 ...
PMID:Active immunization of children with leukemia and other malignancies. 847 77

Many childhood diseases can be prevented by proper immunization. The purpose of this article is to provide information about the risks and benefits associated with vaccines used in the United States for children under one year of age. Vaccines can be made from live or killed organisms and can stimulate both local and systemic immunity. The immunization schedule recommended by the American Academy of Pediatrics is presented. Information about the use of routine vaccines, their risks and the diseases they prevent, is presented. Vaccines included are diphtheria, pertussis, tetanus, poliomyelitis, Haemophilus influenzae, influenza viruses and hepatitis B. Research is ongoing to develop new vaccines and improve those currently in use.
 ...
PMID:Prevention of childhood diseases through vaccination. 847 10

By 1995, measles, mumps, and rubella were eliminated from Finland, acellular vaccines for pertussis were showing great promise, and the global eradication of poliomyelitis by the year 2000 looked possible. The meningococcus was replacing Haemophilus influenzae type b as the main cause of childhood meningitis, and 75 countries were vaccinating their children against hepatitis B. The United States recommended varicella vaccination for children, effective vaccines were available for hepatitis A, and new vaccines for rotavirus and cholera were being tested; malaria and HIV offer a continuing challenge.
 ...
PMID:Update on immunization. 868 May 9

A recombinant hepatitis B vaccine was administered to over 5000 infants in a prospective, randomized and blinded study. Infants were given either recombinant hepatitis B vaccine (Engerix-B, SmithKline Beecham Pharmaceuticals, 10 micrograms dose-1) or a Haemophilus influenzae type b (Hib) conjugate vaccine at 2, 4 and 6 months of age simultaneously with diphtheria-tetanus-pertussis and oral polio vaccines. Adverse reactions were ascertained by parental reports and interviews, and review of medical records. Blood specimens collected from 269 infants given hepatitis B vaccine were assayed for antibody to hepatitis B surface antigen (anti-HBs) by enzyme immunoassay. Infants given hepatitis B vaccine experienced low rates of adverse reactions that were similar or lower than the rates in infants given Hib conjugate vaccine. The geometric mean anti-HBs concentrations were 9.6 mIU ml-1 after one dose, 333 mIU ml-1 after two doses and 1812 mIU ml-1 after three doses (99% had levels > or = 10 mIU ml-1). Antibody responses to diphtheria and tetanus toxoids were unaffected by simultaneous administration of hepatitis B or Hib conjugate vaccine. Engerix-B vaccine was safe and immunogenic when given with other routine childhood immunizations at 2, 4 and 6 months of age, and should provide long-term protection against hepatitis B virus infection.
 ...
PMID:Safety and immunogenicity of a recombinant hepatitis B vaccine administered to infants at 2, 4 and 6 months of age. The Kaiser-UCLA Vaccine Study Group. 881 29

SB-3 (Infanrix-DTPa) is one of a new generation of vaccines for immunisation against pertussis (whooping cough), diphtheria and tetanus. It is a 3-component (pertussis toxin, filamentous haemagglutinin and pertactin) chemically inactivated acellular pertussis pertussis-diphtheria-tetanus toxoid (DTaP) vaccine, and it differs from conventional whole-cell pertussis-diphtheria-tetanus toxoid (DTwP) vaccines in that it comprises inactivated purified Bordetella pertussis antigens rather than whole cells of the bacillus. SB-3, like a number of other DTaP vaccines, elicits a similar or more often, a significantly greater immune response than various DTwP vaccines in healthy infants and young children. initial data from comparative studies indicate that SB-3 also remains immunogenic when given in combination with hepatitis B vaccine or concurrently administered with Haemophilus influenzae type b (HbOC) conjugate vaccine. A combination of SB-3 and H. influenzae type b tetanus (PRP-T) conjugate vaccine results in lower anti-PRP antibody response than when both vaccines are administered concurrently. Data from two large, multicentre, German and Italian studies in infants indicate that the protective efficacy of SB-3 against pertussis was significantly better than one DTwP (DTwP-CON) but similar to another one (DTwP-BW) under investigation. Compared with another DTaP vaccine (BIO-3), SB-3 was just as protective. Overall, the data from these 2 studies indicate that primary vaccination with SB-3 provides effective protection against pertussis, even under the stringent conditions of a household contact with typical pertussis. As the other DTaP vaccines, SB-3 is better tolerated than DTwP vaccines, with a significantly lower incidence of common adverse events such as local reactions (swelling, pain and a erythema), irritability, fever, persistent crying and local tenderness. Clinical experience with SB-3 thus far indicates that, like other DTaP vaccines, it is associated with significantly fewer common (non-serious) adverse events than DTwP vaccines. Less clear is whether it has any advantage over DTwP vaccines with respect to protective efficacy or over other DTaP vaccines with respect to tolerability and protective efficacy. Nevertheless, the available data support the use of SB-3 for infant immunisation, as well as providing a suitable basis for the development of new combination vaccines.
 ...
PMID:A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection. 884 42

Immunization against Haemophilus influenzae b and hepatitis B during infancy, as well as the administration of a second dose of measles-mumps-rubella vaccine around the age of 12, are the significant additions brought to the childhood immunization program in recent years. The availability in the near future of the acellular pertussis vaccines illustrates the efforts made to reduce the side effects associated with the use of some vaccines. The high cost of these acellular vaccines, together with the absence of combined Haemophilus influenzae or hepatitis B vaccines, represent their current limitations.
 ...
PMID:[Vaccination of children in 1996]. 892 55

The article gives a review of the literature concerning immunization of preterm infants. The initial response to diphtheria-tetanus-whole-cell-pertussis vaccine and inactivated polio vaccine may be impaired in preterms, but after two and three doses the responses to these vaccines is comparable to those of term infants of the same chronological age. Likewise, the response to oral polio vaccine is normal and independent of gestational age after two and three doses in preterm infants. After two doses, the response to Haemophilus influenzae type b conjugate vaccine is impaired in preterm infants with very low gestational age, but comparable to that of term infants in preterms with higher gestational ages. After three doses the response to this vaccine is normal and unaffected by gestational age in preterms. Recombinant hepatitis b vaccine induces a reduced response in preterm infants even after three doses, and they may therefore need an extra dose of this vaccine. Studies of diphtheria-tetanus-whole-cell-pertussis vaccine and Haemophilus influenzae type b conjugate vaccine in preterm infants do not suggest that adverse effects occur more often or are more severe than those seen in term infants. The literature provides no background for postponement of immunizations in preterm infants.
 ...
PMID:[Vaccination of premature infants]. 899 75

Since publication of the recommended childhood immunization schedule in July 1996, the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP) have made important changes in recommendations for preventing pertussis and poliomyelitis. Following the licensure of two acellular pertussis vaccines for infants, the advisory groups now recommend use of acellular pertussis vaccine (Tripedia or ACEL-IMUNE) as the preferred vaccine for pertussis vaccination for infants beginning at age 2 months. To reduce the risk for vaccine-associated paralytic poliomyelitis (VAPP), recommendations for poliovirus vaccination have expanded the use of inactivated poliovirus vaccine (IPV) by providing three options for poliovirus vaccination (sequential IPV/oral poliovirus vaccine [OPV], all IPV, or all OPV). In addition, a combination Haemophilus influenzae type b (Hib) and hepatitis B vaccine and a combination diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) and Hib vaccine have been licensed for use in certain situations. This report presents the recommended childhood immunization schedule for 1997 and explains the changes that have occurred since the last publication of the schedule.
 ...
PMID:Recommended childhood immunization schedule--United States, 1997. 901 82


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>